Study Overview:

This study looks at how safe and effective a medicine called amlitelimab is for people who have serious skin problems called moderate to severe atopic dermatitis (AD). Amlitelimab has been used in past trials, and this study will continue to check how well it works and if it is safe. People in the study will visit the clinic every 4 weeks. Some might stop taking the medicine to see if their skin stays better, and if their skin gets worse, they can start taking the medicine again.

Key Points:

• Participants may have clinic visits every 4 weeks or get medicine at home.
• Participants must have been in a previous amlitelimab trial for AD.
• Safety checks will continue 140 days after stopping amlitelimab.

Eligibility:

Participants must be at least 12 years old and have been in a previous amlitelimab trial, completing all necessary steps. They should not have certain medical conditions that could affect participation, like serious infections or other severe diseases.